Additionally, the 36-month beta value for BNTX is 0.99. There are mixed opinions on the stock, with 12 analysts rating it as a “buy,” 5 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for BNTX is 235.99M and currently, short sellers hold a 1.28% ratio of that float. The average trading volume of BNTX on March 06, 2025 was 717.28K shares.
BNTX) stock’s latest price update
The stock price of BioNTech SE ADR (NASDAQ: BNTX) has dropped by -2.13 compared to previous close of 114.77. Despite this, the company has seen a gain of 3.24% in its stock price over the last five trading days. reuters.com reported 2025-03-05 that A German court in Duesseldorf on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna.
BNTX’s Market Performance
BNTX’s stock has risen by 3.24% in the past week, with a monthly drop of -4.11% and a quarterly drop of -4.16%. The volatility ratio for the week is 4.49% while the volatility levels for the last 30 days are 4.33% for BioNTech SE ADR The simple moving average for the past 20 days is -2.92% for BNTX’s stock, with a 7.28% simple moving average for the past 200 days.
Analysts’ Opinion of BNTX
Many brokerage firms have already submitted their reports for BNTX stocks, with Truist repeating the rating for BNTX by listing it as a “Buy.” The predicted price for BNTX in the upcoming period, according to Truist is $172 based on the research report published on January 10, 2025 of the current year 2025.
Wells Fargo, on the other hand, stated in their research note that they expect to see BNTX reach a price target of $170. The rating they have provided for BNTX stocks is “Overweight” according to the report published on December 11th, 2024.
BNTX Trading at -3.81% from the 50-Day Moving Average
After a stumble in the market that brought BNTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.58% of loss for the given period.
Volatility was left at 4.33%, however, over the last 30 days, the volatility rate increased by 4.49%, as shares sank -8.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.85% upper at present.
During the last 5 trading sessions, BNTX rose by +3.21%, which changed the moving average for the period of 200-days by +20.77% in comparison to the 20-day moving average, which settled at $115.70. In addition, BioNTech SE ADR saw -1.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BNTX starting from Richardson Ryan, who proposed sale 26,500 shares at the price of $114.00 back on Feb 27 ’25. After this action, Richardson Ryan now owns shares of BioNTech SE ADR, valued at $3,021,000 using the latest closing price.
Medine GmbH, the Officer of BioNTech SE ADR, proposed sale 1,000,000 shares at $119.58 during a trade that took place back on Feb 20 ’25, which means that Medine GmbH is holding shares at $119,580,000 based on the most recent closing price.
Stock Fundamentals for BNTX
Current profitability levels for the company are sitting at:
- -0.23 for the present operating margin
- 0.84 for the gross margin
The net margin for BioNTech SE ADR stands at -0.16. The total capital return value is set at -0.03. Equity return is now at value -2.37, with -2.07 for asset returns.
Based on BioNTech SE ADR (BNTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 6.39. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -17.5.
Currently, EBITDA for the company is 1.09 billion with net debt to EBITDA at 104.32. When we switch over and look at the enterprise to sales, we see a ratio of 5.1. The receivables turnover for the company is 2.52for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.33.
Conclusion
In conclusion, BioNTech SE ADR (BNTX) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
